Abstract library

232 results for "pfs".
#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs
Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Mark Kidd
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...
#795 Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET): A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS)
Introduction: OCT has shown antitumor activity and significantly prolonged time to tumor progression vs PBO in pts with metastatic midgut NET (PROMID).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Jonathan R Strosberg
#1126 Long-Term Follow-Up and Survival Data in Progressing Advanced Midgut Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment option for advanced Neuroendocrine Tumours (NET), however long term survival data is lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT, PFS, OS
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#2286 A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan
#341 Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results
Introduction: In previous phase II studies of EVE in patients with pNET, those with elevated baseline Chromogranin A (eCgA) and neuron-specific enolase (eNSE) levels experienced shorter PFS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kjell Oberg
Authors: Oberg K, Anthony L, Sideris L, Chen L T, ...
#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors
Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Tingting Li
Authors: Li T, Qian Z, Ter-Minassian M, Chan J A, ...
Keywords: SSTR2, SSA, NET, OS, PFS
#1194 Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study
Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
Keywords: lanreotide, biomarker
#1336 Resection of the Primary Tumor Prior to Peptide Receptor Radionuclide Therapy Improves Treatment Response and Progression-free Survival in Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases
Introduction: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Bodei L, ...